FLT3 and acute myeloid leukemia: The approval of multikinase FLT3 inhibitor (FLT3i) midostaurin with induction therapy for newly diagnosed FLT3mut AML, and a more specific and potent FLT3i gilteritinib as monotherapy for relapsed/refractory (R/R) FLT3mut AML, has improved outcomes in patients with FLT3-mutated AML (4, 5).